IN8bio (INAB) vs Tempest Therapeutics (TPST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
IN8bio (INAB) has outperformed Tempest Therapeutics (TPST) over the past year, losing 42.7% versus a loss of 93.0%. Over five years, INAB leads with a -99.2% price change compared with -99.6% for TPST. IN8bio is the larger company by market cap ($13.2 million vs $12.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INAB | TPST |
|---|---|---|
| Share price | $1.34 | $0.7601 |
| Market cap | $13.21M | $12.84M |
| 1-day change | -2.90% | -1.29% |
| YTD return | -41.03% | -73.17% |
| 1-year return | -42.74% | -92.99% |
| 5-year return | -99.23% | -99.60% |
| EPS (TTM) | $-1.62 | $-3.93 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.73 | $12.23 |
| 52-week low | $0.88 | $0.743 |
| Distance from 52-week high | -50.92% | -93.78% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +422.39% | +820.93% |
| Average volume | 58.36K | 2.60M |
| Shares outstanding | 9.86M | 16.89M |
| Employees | 18 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INAB has outperformed TPST by 50.2 percentage points over the past year.
About IN8bio
INAB stock →IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
About Tempest Therapeutics
TPST stock →Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
INAB vs TPST FAQ
Which is bigger, IN8bio or Tempest Therapeutics?
IN8bio (INAB) is larger, with a market capitalization of $13.21M compared with $12.84M for Tempest Therapeutics (TPST).
Which stock has performed better over the past year, INAB or TPST?
INAB returned -42.74% over the past 12 months, compared with -92.99% for TPST (price return, excluding dividends). Past performance does not predict future results.
Are IN8bio and Tempest Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for IN8bio and Biotechnology: Pharmaceutical Preparations for Tempest Therapeutics.